EVIDENCE BASE
Selected Published Research
Peer-reviewed studies underpinning the Vectus Biosystems approach to understanding and reversing fibrotic disease.
Vasoactive intestinal peptide infusion reverses existing renal interstitial fibrosis via a blood pressure independent mechanism in the rat.
Duggan KA, Hodge G, Chen J, Trajanovska S, Hunter T. European Journal of Pharmacology. 2020;873:172979. DOI: 10.1016/j.ejphar.2020.172979. PMID: 32014488.
Vasoactive intestinal peptide infusion reverses existing myocardial fibrosis in the rat.
Duggan KA, Hodge G, Chen J, Hunter T. European Journal of Pharmacology. 2019;862:172629. DOI: 10.1016/j.ejphar.2019.172629. PMID: 31449808.
Vasopeptidase inhibition reverses myocardial vasoactive intestinal peptide depletion and decreases fibrosis in salt sensitive hypertension.
Ye VZ, Hodge G, Yong JL, Duggan KA. European Journal of Pharmacology. 2004;485(1-3):235-242. DOI: 10.1016/j.ejphar.2003.11.069. PMID: 14757146.
Myocardial vasoactive intestinal peptide and fibrosis induced by nitric oxide synthase inhibition in the rat.
Ye VZ, Hodge G, Yong JL, Duggan KA. Acta Physiologica Scandinavica. 2003;179(4):353-360. DOI: 10.1046/j.0001-6772.2003.01200.x. PMID: 14656372.
Early myocardial fibrosis is associated with depletion of vasoactive intestinal peptide in rat heart.
Ye VZ, Hodge G, Yong JL, Duggan KA. Experimental Physiology. 2002;87(5):539-546. DOI: 10.1113/eph8702335. PMID: 12481928.